stockrowOutset Medical, Inc.
Outset Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $119.5 million, up 5.09% from fiscal 2024.
- Revenue
- +14.2%
- EPS
- +22.0%
- Free cash flow
- −61.9%
- Total debt
- +4.20%
Quarter to September 2026, against a year earlier
Follow OM
Alert me
Outset Medical, Inc. (OM) EV/Sales
As of 5 November 2026, Outset Medical, Inc. (OM) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −0.2× (April 2025) to 35.3× (April 2021); the current reading is higher than 20% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.1× | — |
| FY2024 | 0.9× | (46.17%) |
| FY2023 | 1.6× | (81.82%) |
| FY2022 | 8.8× | (49.94%) |
| FY2021 | 17.5× | 35.14% |
| FY2020 | 12.9× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 0.2× | (44.37%) |
| Jun 2026 | 0.3× | 178.45% |
| Mar 2026 | 0.1× | — |
| Dec 2025 | −0.1× | — |
| 24 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NYXH Nyxoah SA compare | 0.1× |
| OM Outset Medical, Inc. | 0.3× |
| LNSR LENSAR, Inc. compare | 1.0× |
| ZOMDF Zomedica Corp. compare | 1.3× |
| ECOR electroCore, Inc. compare | 2.1× |
| HYPR Hyperfine, Inc. compare | 2.3× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| MBOT Microbot Medical Inc. compare | 15.0× |
| SERA Sera Prognostics, Inc. compare | 641× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)